CapyBio
2 known investors
Find your way into CapyBio
369 people in our graph share verified history with the CapyBio team — schools, employers, funds. One of them is your warm intro.
Vivek Gopalanunlockedknows Guillermo Rivera · together at Yale University (overlapped)
knows the team · via Yale University
×5knows the team · via Harvard Medical School
×2knows the team · via ETH Zurich
×3knows the team · via University of York
CapyBio provides tools to measure how closely cells match a target identity and to improve them, helping scientists and biopharma teams reduce failure in drug discovery, build stronger disease models, and advance cell-based therapies. The company applies cell biology and computational methods to cell identity for research, testing, and regenerative medicine.
Founders & leadership
GR
Guillermo RiverainInterim CEO, Co-Founder & CSOGuillermo Rivera holds a Ph.D. in Biology and has held positions as a Senior Scientist and Postdoctoral Associate at leading institutions, where he developed expertise in stem cell research, single-cell sequencing, and gene therapy, with published work in adipocyte differentiation and cell lineage tracing. He is Interim CEO, Co-Founder, and Chief Scientific Officer of CapyBio, which develops tools to measure and improve cell identity for drug discovery and cell-based therapeutic applications.
SM
Samantha MorrisCo-Founder
KJ
Kunal JindalinCo-Founder & CTOHe has research expertise in single-cell and spatial genomics, stem cell biology, and machine learning, with a focus on developing tools for analyzing biological systems.
Investors · 2
Competitors · 4
by search overlap
Bridgebio4 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
AskBio3 shared keywordsAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.
Capio Biosciences3 shared keywordsCapio Biosciences develops the CapioCyte platform, an ultra-sensitive technology for capturing and analyzing circulating tumor cells (CTCs) from whole blood. The oncology diagnostics tool is aimed at cancer research and potential future clinical use to support treatment decisions.
PipeBio3 shared keywordsPipeBio provides a bioinformatics platform for drug discovery that enables scientists and bioinformaticians to analyze genomic and assay data. The platform combines sequence data management, machine learning tools, and visualization capabilities to accelerate therapeutic development for academia, biotech companies, and pharmaceutical firms.
Companies competing with CapyBio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does CapyBio do?
- CapyBio provides tools to measure how closely cells match a target identity and to improve them, helping scientists and biopharma teams reduce failure in drug discovery, build stronger disease models, and advance cell-based therapies. The company applies cell biology and computational methods to cell identity for research, testing, and regenerative medicine.
- Who founded CapyBio?
- CapyBio was founded by Guillermo Rivera, Samantha Morris, Kunal Jindal.
- Who are CapyBio's investors?
- CapyBio's investors include Missouri Technology Corporation, Cultivation Capital.